Akebia Therapeutics
AKBA
145 hedge funds and large institutions have $339M invested in Akebia Therapeutics in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 49 increasing their positions, 45 reducing their positions, and 17 closing their positions.
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
15% more capital invested
Capital invested by funds: $294M → $339M (+$44.8M)
1% more funds holding
Funds holding: 143 → 145 (+2)
9% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 45
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.3% less ownership
Funds ownership: 71.81% → 65.51% (-6.3%)
40% less call options, than puts
Call options by funds: $2.14M | Put options by funds: $3.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.7M |
| 2 |
Morgan Stanley
New York
|
+$11.1M |
| 3 |
Citigroup
New York
|
+$3.93M |
| 4 |
BlackRock
New York
|
+$3.5M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19.6M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$6.81M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$6.67M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.31M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$3.49M |
AKBA Hedge Fund Activity: Q1 2021 in Review
145 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2021, worth a combined $339M — up 15% from $294M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AKBA positions and 17 closed out — a net gain of 3 holders — while 49 added to existing stakes and 45 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.7M. The largest seller was State Street, cutting an estimated $19.6M.
- 145 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2021, up from 143 in Q4 2020.
- Funds reported $339M of Akebia Therapeutics stock for Q1 2021, up 15% quarter-over-quarter.
- 20 funds opened new Akebia Therapeutics positions in Q1 2021 and 17 closed out, a net change of +3 holders.
- The largest Akebia Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $11.7M added.
- The largest Akebia Therapeutics seller in Q1 2021 was State Street, an estimated $19.6M sold.
Based on aggregated 13F filings for Q1 2021.